Female libido med Addyi hits U.S. pharmacies; Sanofi launches PCSK9 med Praluent in U.K.;

> Sprout Pharmaceuticals rolled out the controversial female libido drug Addyi on Saturday, and analysts are saying that safety issues with the med could spur development of better follow-up drugs. Report

> Sanofi ($SNY) and Regeneron ($REGN) rolled out their cholesterol-fighting PCSK9 drug Praluent in the U.K., going up against Amgen's ($AMGN) Repatha, which launched there last month. Report

> Drugmakers prevailed in their latest fight against 340B hospital discounts on orphan drugs in nonorphan indications. Report

> Johnson & Johnson ($JNJ) won its first lawsuit over Tylenol and its potential links to liver damage; the company faces more than 200 similar claims of a design defects in the popular pain reliever. Report

And Finally... The Novartis ($NVS) cancer drug Tasigna delivered "meaningful clinical improvements" in 10 of 11 Parkinson's disease patients in an early-stage trial. Report

Suggested Articles

Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.